For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
News Release
FDA commissioner resignation opens opportunity for refocus on science over politics
After a somewhat tumultuous tenure, FDA commissioner Marty Makary is stepping down. While Dr. Makary made his mission to accelerate drug approval and bring a…
Blog
Don’t hinder biosimilar development
In its most recent legislative session, the Florida legislature considered precluding pharmacy benefit managers (PBMs) from holding an investment interest in biosimilar manufacturing. That…
Blog
The unseen costs of banning PBM-owned pharmacies in Tennessee
Tennessee lawmakers recently passed the FAIR Rx Act, which would bar companies from owning pharmacies while also operating a pharmacy benefit manager (PBM) and…
Search Posts
Washington Times
High Price of Cheap Drug Imports
With the Senate set to vote on one of the few “must-pass” bills of the year, pharmaceutical industry critics are plotting ways to add poison…
Blog
More First Amendment Violations from Obamacare, Thanks to HHS
Obamacare will drive up costs for most patients and insurance policyholders. Yet "health-insurance companies must tell customers who get a premium rebate…
Washington Times
ObamaCare’s Killer Device Tax
Much of the political conversation in Washington these days concerns innovation, job creation and competitiveness. But talk is cheap, and elected officials must enact policies…
Washington Times
The Off-Label Drug War of Words
If knowledge is power and ignorance is bliss, what is power used to prevent knowledge from eliminating ignorance? I don’t know; ask the FDA (U.S.
Heartlander
Critical Drug Shortages Reaching Crisis
From Ashley Bateman's article on Heartland.org: But according to Greg Conko, a senior fellow at the Competitive Enterprise Institute, more mandates on companies…
Medical Progress Today
Mayo v. Prometheus and Diagnostic Patents: What Does the Supreme Court Decision Really Mean?
I finally had a chance to read the Supreme Court's recent decision in the Mayo v. Prometheus Labs case, which invalided two patents claiming methods…
